Please login to the form below

Not currently logged in
Email:
Password:

Sue Mahony to retire as president of Lilly Oncology

She will continue in her position until August 31

Eli LillyEli Lilly’s senior vice president and president of Lilly Oncology, Sue Mahony, is set to retire at the end of August after 18 years of service with the company.

Mahony led Lilly Oncology through the integration of ImClone and launched several brands including Verzenio.

She also most recently led the refocusing of the company’s oncology R&D strategy.

Prior to this, as senior vice president of human resources and diversity, Mahony played in a role in restructuring the company into business units.

She said: “What I’ve appreciated over the years is the opportunity to participate in something greater than myself.

“We make medicines that help patients with cancer live longer and what a privilege it’s been to wake up each morning with that as my life’s work.”

Prior to her time with Eli Lilly, Mahony has served in various roles for Amgen, Bristol-Myers Squibb and Schering-Plough.

Lilly has said it is considering internal and external candidates to find Mahony’s successor.

5th June 2018

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics